Tirzepatide Beats Semaglutide for Fat Loss, but Not Because It Kills Appetite More | Research

The takeaway

Tirzepatide reduced fat mass more than semaglutide despite both drugs suppressing appetite equally, suggesting tirzepatide's extra weight loss comes from metabolic effects beyond eating less.

Equal appetite, unequal fat loss
Tirzepatide and semaglutide suppressed appetite equally, yet tirzepatide produced significantly more fat mass reduction — pointing to metabolic mechanisms beyond hunger control

What the researchers found

Tirzepatide 15 mg produced significantly greater body weight and fat mass reductions compared to both semaglutide 1 mg and placebo over 28 weeks in type 2 diabetes patients. Both tirzepatide and semaglutide significantly reduced appetite versus placebo, but appetite scores and energy intake reductions during ad libitum lunch did not differ between the two drugs.

This surprising finding — that tirzepatide and semaglutide suppress appetite equally but tirzepatide produces more weight loss — suggests tirzepatide's superior weight loss involves mechanisms beyond appetite reduction, possibly including effects on 24-hour energy intake, substrate utilization, or energy expenditure.

Why it matters

Tirzepatide consistently produces more weight loss than semaglutide in clinical trials, but why has been unclear. This study reveals that appetite suppression alone doesn't explain the difference — both drugs reduce hunger similarly. This means the dual GIP/GLP-1 mechanism of tirzepatide must provide additional metabolic benefits, possibly through increased fat burning or energy expenditure, that go beyond simply eating less. Understanding these mechanisms could inform the development of even more effective peptide-based obesity treatments.

The numbers in context

N=117 (45 tirzepatide, 44 semaglutide, 28 placebo) · 28 weeks · Greater fat mass reduction with tirzepatide · Equal appetite suppression between drugs · Energy intake difference insufficient to explain weight outcomes

How the study worked

Secondary analysis of a randomized, double-blind, parallel-arm Phase 2 study. Type 2 diabetes patients received tirzepatide 15 mg (n=45), semaglutide 1 mg (n=44), or placebo (n=28) for 28 weeks. Body composition was assessed (fat mass vs lean mass). Appetite was measured by visual analog scales. Energy intake was measured during ad libitum lunch meals.

Who was studied

Adults with type 2 diabetes randomized to tirzepatide 15 mg, semaglutide 1 mg, or placebo

What this study cannot tell us

This is a secondary analysis of a trial not primarily designed for these endpoints. The sample size is small (117 total). Energy intake was only measured during a single ad libitum lunch, not over 24 hours — other meals may differ. Semaglutide was dosed at 1 mg (not 2.4 mg, the obesity dose), so the comparison may not reflect maximal semaglutide efficacy. The mechanisms explaining tirzepatide's greater weight loss were not identified, only that appetite reduction isn't sufficient.

How to read the evidence

This is a secondary analysis of a randomized, double-blind Phase 2 trial — well-designed but small (n=117) and not powered for the specific endpoints analyzed. The semaglutide dose (1 mg) is below the obesity-indicated dose.

When this study was published

Published in 2023 in Diabetes Care, a top-tier journal. This study framed a key question in the field — what explains tirzepatide's weight-loss advantage — that continues to drive research.

The bigger picture

This finding has major implications for the peptide drug obesity pipeline. If tirzepatide's advantage over semaglutide isn't about appetite, then the GIP receptor — which tirzepatide activates but semaglutide doesn't — may drive metabolic benefits like fat oxidation or energy expenditure. This supports development of drugs that target metabolic pathways beyond appetite, potentially leading to even more effective weight-loss medications.

Questions still open

Does GIP receptor agonism increase energy expenditure or fat oxidation independently of appetite suppression?
Would 24-hour energy intake measurements (not just lunch) reveal differences between tirzepatide and semaglutide?
Could the metabolic advantage of tirzepatide be enhanced further by adding glucagon agonism (triple agonists)?

Common questions

If both drugs reduce appetite equally, why does tirzepatide cause more weight loss?

That's the key mystery this study reveals. Tirzepatide activates two receptors (GIP and GLP-1) while semaglutide activates only GLP-1. Since the appetite suppression is similar, the GIP receptor activation in tirzepatide likely drives additional metabolic effects — possibly increased fat burning, higher energy expenditure, or changes in how the body stores and uses energy — that haven't been fully characterized yet.

Should I choose tirzepatide over semaglutide for weight loss?

This study suggests tirzepatide may have metabolic advantages for fat loss beyond what semaglutide offers, but the comparison used semaglutide's diabetes dose (1 mg), not its higher weight-loss dose (2.4 mg). Both drugs are effective for weight management. The choice between them should consider individual factors like insurance coverage, side effect tolerance, and your doctor's recommendation.

Read the original research

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

Diabetes care, 46(5), 998-1004

View on PubMed ↗Publisher’s paper ↗

Citation

Heise, Tim; DeVries, J Hans; Urva, Shweta; Li, Jing; Pratt, Edward J; Thomas, Melissa K; Mather, Kieren J; Karanikas, Chrisanthi A; Dunn, Julia; Haupt, Axel; Milicevic, Zvonko; Coskun, Tamer. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.. Diabetes care, 46(5), 998-1004. https://doi.org/10.2337/dc22-1710